Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if the combination of docetaxel,
cisplatin, irinotecan and bevacizumab will help shrink metastatic esophageal or gastric
cancer and how the cancer responds to this combination. Bevacizumab is a new drug that is
believed to stop the formation of new blood vessels that carry nutrients to tumors.
Bevacizumab is approved for use in metastatic colon and rectal cancer. Docetaxel, cisplatin
and irinotecan are traditional chemotherapy agents that have been tested together in another
clinical trial for esophageal and gastric cancer. It is hoped that adding bevacizumab to this
regimen will make the treatment more effective.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital